Vita Life SciencesASX:VLS +0.82%92 Debt-to-Equity is 0.04 as of Dec. 2025, which is 33% below its 10-year median of 0.06. GuruFocus rates ASX:VLS with a GF Score™ of 92/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 810 Drug Manufacturers companies, Vita Life Sciences ranks better than 84.81% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vita Life Sciences's Debt-to-Equity or its related term are showing as below:
ASX:VLS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.06 Max: 0.11
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Vita Life Sciences was 0.11. The lowest was 0.01. And the median was 0.06.
ASX:VLS's Debt-to-Equity is ranked better than 84.81% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ASX:VLS: 0.04
Vita Life Sciences (ASX:VLS) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vita Life Sciences Debt-to-Equity Related Terms
Vita Life Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Debt-to-Equity of 0.04 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vita Life Sciences and its competitors. This is 33% below median its historical median of 0.06. Over the past decade, Vita Life Sciences' Debt-to-Equity has ranged from 0.01 to 0.11. According to the industry distribution chart, Vita Life Sciences ranks #123 out of 810 companies in the Drug Manufacturers industry, placing it in the top 15.2%.
Is Vita Life Sciences' Debt-to-Equity too high?
Vita Life Sciences' current Debt-to-Equity of 0.04 is 33% below median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.11. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Vita Life Sciences' value of 0.04 is 85.2% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #123 out of 810 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #123 out of 810 companies for Debt-to-Equity. This places Vita Life Sciences in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Vita Life Sciences' value of 0.04 is 85.2% below this benchmark. Historically, Vita Life Sciences' own Debt-to-Equity has ranged from 0.01 to 0.11 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.27, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Debt-to-Equity of 0.04 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Debt-to-Equity is 0.04, which is 33% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.47 — trading 0.4% below its estimated fair value. The current Debt-to-Equity is 0.04, which is 33% below median its 10-year median of 0.06 and 85.2% below the Drug Manufacturers industry median of 0.27. Vita Life Sciences' overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Debt-to-Equity is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.47 is trading 0.4% below its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Debt-to-Equity: 0.04 (33% below median its 10-year median of 0.06)
GF Value™: A$2.48 vs. price of A$2.47 (0.4% below fair value)
Industry Position: 85.2% below the Drug Manufacturers median (#123 of 810)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
92GF Score
Get the complete analysis for ASX:VLS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
